MLYCD

Across TCGA pan-cancer cohorts, MLYCD Mutation is linked to patient survival in 4 of 34 cancer types, making it a survival-associated MLYCD data layer compared with 22 for mass-spec protein and 7 for mass-spec protein.

The strongest signal is observed in bladder urothelial carcinoma (BLCA), where higher MLYCD Mutation is associated with worse disease-free survival. In most high-consensus cancer types, elevated MLYCD expression acts as an unfavorable survival marker, although some lineages such as UCEC show a favorable association.

BLCA, LUSC, and HNSC are the cancer types where MLYCD Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
BLCA	DFS	Median	IV	0.081	0.480	<.001	12	view →
LUSC	OS	Median	II,III,IV	0.273	0.742	.028	9	view →
HNSC	DFS	Median	All	0.233	0.628	.037	6	view →
UCEC	DFS	Median	All	1.000	0.635	.028	4	view →

Pink = unfavorable, green = favorable. Showing the 4 strongest of 4 lineages.

MLYCD–BLCA (DFS)

Open the BLCA breakdown →